Verified ACRP-CP Dumps Q&As - ACRP-CP Test Engine with Correct Answers
Pass Your ACRP-CP Dumps as PDF Updated on 2025 With 127 Questions
NEW QUESTION # 53
Who is responsible for the ongoing safety evaluation of the IP?
- A. Regulatory agency
- B. IRB/IEC
- C. Sponsor
- D. PI
Answer: C
Explanation:
The sponsor is primarily responsible for the ongoing safety evaluation of the investigational product (IP) throughout the clinical trial. This responsibility includes monitoring adverse events, reporting serious adverse events (SAEs) to regulatory authorities, and updating the Investigator's Brochure (IB) with relevant safety data.
According to GCP guidelines, the sponsor must continuously evaluate safety data and report findings to regulatory bodies as necessary.
"The sponsor is responsible for the continuous safety monitoring of the investigational product and for ensuring that new safety information is communicated to investigators and regulators." Objectives:
* Ensure participant safety throughout the study.
* Maintain accurate and timely reporting of safety data.
NEW QUESTION # 54
Upon receipt of temperature-controlled IP, the study staff noticed the IP incurred a temperature excursion during transport. What should the staff do NEXT?
- A. Dispose of IP and request replacement from sponsor.
- B. Register IP in IWRS and continue with subject allocation.
- C. Quarantine IP without registering in IWRS and request replacement from sponsor.
- D. Register IP in IWRS, quarantine and notify sponsor of the excursion.
Answer: D
Explanation:
If a temperature-controlled IP has experienced a temperature excursion during transport, the appropriate action is to register the IP in the Interactive Web Response System (IWRS), quarantine it to prevent use, and immediately notify the sponsor. This procedure ensures that the IP is not used until the sponsor evaluates its stability and suitability.
GCP guidelines state that any IP affected by a temperature excursion should be quarantined and reported to the sponsor for evaluation.
"Upon identification of a temperature excursion, the IP must be quarantined and reported to the sponsor to determine its usability." Objectives:
* Maintain IP integrity and compliance with storage conditions.
* Follow protocol for managing temperature excursions.
NEW QUESTION # 55
Which of the following should be considered when implementing a risk-based monitoring plan?
- A. 100% source document review is mandatory.
- B. On-site monitoring frequency may change depending on the quality of the data.
- C. Monitoring schedule must be pre-defined in the monitoring plan.
- D. Centralized monitoring must be incorporated in any trials.
Answer: B
Explanation:
Risk-based monitoring focuses on adapting the frequency and intensity of on-site visits based on data quality and site performance. If the data is consistently accurate and reliable, the monitoring frequency may be reduced. Conversely, if issues are identified, more frequent monitoring may be necessary.
GCP guidelines emphasize a flexible approach to monitoring, allowing adjustments based on the risk profile and quality of data collected.
"Risk-based monitoring involves adapting the frequency of on-site visits according to the quality of the data and the site's compliance level." Objectives:
* Implement a dynamic monitoring strategy.
* Enhance efficiency while maintaining data integrity.
NEW QUESTION # 56
The composition of an IDMC/DSMB should include which one of the following?
- A. A clinical scientist who is knowledgeable in the appropriate discipline
- B. A sponsor representative who is knowledgeable about the study's unblinded information
- C. A member from the IRB/IEC
- D. A lead PI for the study
Answer: A
Explanation:
An Independent Data Monitoring Committee (IDMC) or Data and Safety Monitoring Board (DSMB) should include clinical scientists who are knowledgeable in the relevant medical and scientific areas. Their role is to objectively assess the ongoing safety data and efficacy of the investigational product, ensuring that participants' safety is not compromised.
GCP guidelines emphasize the need for experienced clinical scientists on IDMC/DSMBs to ensure that safety data is interpreted accurately and professionally.
"IDMC/DSMB should comprise independent experts, including clinical scientists, who have the expertise to evaluate safety and efficacy data objectively." Objectives:
* Ensure impartial evaluation of safety data.
* Maintain scientific integrity in monitoring clinical trials.
NEW QUESTION # 57
The sponsor calls the site and informs the research team that they have decided to temporarily suspend the study. What step should the research team take FIRST?
- A. Inform participant and assure proper care is provided.
- B. Inform the monitor of the termination of the study.
- C. Inform the IRB/IEC of the study closure.
- D. Schedule participant for early termination visit.
Answer: A
Explanation:
When a study is temporarily suspended, the primary responsibility of the research team is to ensure the ongoing care and safety of the enrolled participants. Participants must be informed about the suspension and assured that their health and safety will continue to be monitored.
GCP guidelines prioritize the safety and well-being of participants, which must be maintained even during a temporary suspension.
"In the event of a study suspension, the first priority is to inform the participants and ensure that appropriate care and monitoring are continued." Objectives:
* Protect participant safety during study suspension.
* Maintain clear communication with study participants.
NEW QUESTION # 58
A clinical trial where participants will be randomized to receive a sequence of two medications has which design configuration?
- A. Crossover
- B. Group sequential
- C. Factorial
- D. Parallel Group
Answer: A
Explanation:
A crossover study design involves participants receiving multiple interventions sequentially, with a washout period in between to minimize carryover effects. This design allows each participant to serve as their own control, increasing statistical power while reducing variability. It is commonly used when comparing two treatments or interventions.
GCP guidelines classify a crossover design as one where subjects receive multiple treatments in a specified sequence.
"In crossover trials, participants receive each intervention in a specific order, allowing for within-subject comparison." Objectives:
* Understand the structure of crossover studies.
* Improve statistical efficiency through self-control comparisons.
NEW QUESTION # 59
When determining whether a protocol deviation (PD) is reportable to the IRB/IEC, the PI should take into consideration whether the:
- A. PD affected participant recruitment.
- B. Participant verbally agreed to the PD.
- C. PD affected participant safety.
- D. Sponsor approved the PD.
Answer: C
Explanation:
The primary factor in determining whether a protocol deviation should be reported to the IRB/IEC is whether the deviation impacts participant safety or the integrity of the study data. Any deviation that could pose a risk to participants must be reported promptly to ensure ongoing ethical oversight.
GCP guidelines mandate reporting of any protocol deviations that affect safety or data integrity to the IRB
/IEC.
"Protocol deviations that impact the safety of participants or the integrity of the study must be reported to the IRB/IEC." Objectives:
* Maintain participant safety.
* Ensure regulatory compliance through prompt reporting.
NEW QUESTION # 60
Per the protocol, participants' blood creatinine level must be no greater than 2.5 times the upper limit of normal (0.7-1.2 mg/dL). What is the maximum creatinine level the participant can have and be eligible for the trial?
- A. 3.0 mg/dL
- B. 2.6 mg/dL
- C. 1.8 mg/dL
- D. 3.6 mg/dL
Answer: A
Explanation:
To calculate the maximum allowable creatinine level, multiply the upper limit of normal (1.2 mg/dL) by 2.5.
1.2 x 2.5 = 3.0 mg/dL
Therefore, the maximum creatinine level that a participant can have to remain eligible for the trial is 3.0 mg
/dL.
GCP guidelines specify that eligibility criteria, including lab values, must be strictly followed to maintain protocol compliance.
"The protocol specifies that laboratory values must not exceed the defined limits to ensure participant safety and data integrity." Objectives:
* Maintain accurate interpretation of laboratory criteria.
* Ensure compliance with protocol-defined inclusion/exclusion criteria.
NEW QUESTION # 61
Which of the following activities would be undertaken by the sponsor to BEST ensure overall quality of the study data?
- A. Conduct annual reviews of the protocol and accompanying study documents.
- B. Ensure submission of a data management plan to the regulatory authorities.
- C. Develop a plan that describes the monitoring approach for a clinical study.
- D. Ensure there is an accompanying written record that describes the consent process.
Answer: C
Explanation:
Developing a monitoring plan that outlines the approach to quality assurance is essential for maintaining data integrity throughout the clinical trial. This plan helps identify critical data points, risk-based monitoring strategies, and procedures for detecting and correcting data discrepancies. It ensures that the study data collected is accurate, complete, and verifiable.
GCP guidelines emphasize the importance of a monitoring plan to safeguard the quality and integrity of study data.
"The sponsor should develop a comprehensive monitoring plan to ensure the accuracy, completeness, and consistency of trial data." Objectives:
* Maintain high-quality data through structured monitoring.
* Identify potential risks and address them proactively.
NEW QUESTION # 62
The primary purpose for IRB/IEC approval of posters, fliers, social media posts, and promotional items is to:
- A. Safeguard the rights, safety, and well-being of all potential subjects.
- B. Confirm subjects receive the appropriate reimbursement.
- C. Assure the ads do not impinge on confidentiality agreements.
- D. Review the content for ethically or morally sensitive issues.
Answer: A
Explanation:
The IRB/IEC's primary responsibility when reviewing recruitment materials such as posters, fliers, social media posts, and promotional items is to ensure that these materials safeguard the rights, safety, and well- being of potential participants. This includes ensuring that the information is presented ethically, clearly, and without coercion, maintaining compliance with ethical guidelines.
GCP guidelines require that any materials used for recruitment be reviewed to ensure they do not mislead participants and that they respect their rights and well-being.
"IRB/IEC review of recruitment materials ensures that they protect participants' rights and well-being and that the content is ethically appropriate." Objectives:
* Maintain ethical standards in recruitment.
* Protect potential participants from misleading or coercive information.
NEW QUESTION # 63
The objective of a randomized clinical trial is to look at whether an IP is effective in preventing recurrence of a disease. What would be a possible primary endpoint of the trial?
- A. Time to occurrence of symptoms of the disease
- B. Occurrence of known side effects of the IP
- C. Use of concomitant medications to treat the symptoms
- D. Impact of an approved vaccine against the disease
Answer: A
Explanation:
In a clinical trial aimed at assessing whether an IP prevents disease recurrence, the primary endpoint would typically be the "time to occurrence of symptoms" indicating a relapse or recurrence. This endpoint directly measures the IP's effectiveness in prolonging the symptom-free period.
This answer follows the GCP guideline, which states that primary endpoints should directly reflect the trial's objectives, particularly when evaluating recurrence prevention.
"In trials evaluating recurrence prevention, the primary endpoint should measure the time until recurrence of the target symptoms or condition." Objectives:
* Assess the efficacy of IP in preventing disease recurrence.
* Accurately measure the time to recurrence as a primary endpoint.
NEW QUESTION # 64
Which of the following documents is maintained by a PI to ensure compliance with sponsor requirements?
- A. A monitoring report that identifies deviation from the approved protocol.
- B. A monitoring plan that is tailored to the specific human subject protection and data integrity risks of the trial.
- C. Training records of site personnel on study protocol, and their study-related duties and functions.
- D. Regulatory submission of protocol and accompanying documents to relevant regulatory authority.
Answer: C
Explanation:
The PI is responsible for maintaining training records of site personnel, which demonstrate compliance with the sponsor's requirements for conducting the trial. Proper documentation of training ensures that all team members are knowledgeable about the protocol and study procedures.
GCP guidelines mandate that the PI maintains adequate records to demonstrate that all personnel involved in the study are properly trained and qualified.
"Training records of site personnel must be maintained to verify that the team is adequately trained on the protocol and their specific responsibilities." Objectives:
* Maintain training compliance.
* Document personnel qualifications for quality assurance.
NEW QUESTION # 65
Who takes responsibility for initiating a clinical trial?
- A. IRB/IEC
- B. Sponsor
- C. CRO
- D. Investigator
Answer: B
Explanation:
The sponsor is responsible for initiating a clinical trial. This involves developing the protocol, securing funding, selecting study sites, and obtaining regulatory approvals. The sponsor also oversees the conduct of the trial to ensure compliance with GCP and regulatory requirements.
According to GCP guidelines, the sponsor is the entity that initiates, manages, and finances the clinical investigation.
"The sponsor is responsible for initiating, managing, and financing the clinical trial, including protocol development and site selection." Objectives:
* Understand the sponsor's role in trial initiation.
* Ensure compliance from the outset of the study.
NEW QUESTION # 66
Prior to initiation of a clinical trial, review by an IRB/IEC is required for which of the following documents?
- A. Protocol, informed consent, and clinical trial agreement
- B. IB, site coordinator CVs, and information about payments and compensation available to subjects
- C. Protocol, IB, and information about payments and compensation available to subjects
- D. Protocol, site coordinator CVs, and clinical trial agreement
Answer: C
Explanation:
Before a clinical trial can begin, the IRB/IEC must review the protocol, Investigator's Brochure (IB), and any information related to payments and compensation. This review ensures that the study is ethically sound, scientifically valid, and that participants are informed about any financial considerations.
GCP guidelines specify that essential documents, including the protocol, IB, and compensation details, must be reviewed by the IRB/IEC to maintain ethical oversight.
"The IRB/IEC must evaluate the protocol, IB, and any financial disclosures to ensure ethical compliance and participant protection." Objectives:
* Guarantee ethical oversight in clinical trial conduct.
* Protect participants through informed consent and transparency.
NEW QUESTION # 67
All site financial matters pertaining to a trial are listed in what document?
- A. Protocol
- B. Financial disclosure
- C. Signed contract
- D. Informed consent form
Answer: C
Explanation:
All financial agreements, including compensation, budgeting, and payment terms related to the conduct of a clinical trial, are documented in the signed contract between the sponsor and the site. This contract outlines the financial responsibilities and ensures transparency and compliance.
GCP guidelines stipulate that financial matters related to the conduct of a trial are to be formally documented in contractual agreements.
"The financial aspects of a clinical trial must be outlined in the signed agreement between the sponsor and the site, ensuring clear understanding of compensation and obligations." Objectives:
* Ensure financial transparency and accountability.
* Maintain compliance with contractual obligations.
NEW QUESTION # 68
A PI is being considered for an industry-sponsored study. The PI sees approximately 20 patients per month who meet the study criteria. The PI does not have access to a Positron Emission Tomography (PET) scanner, which is required for the protocol. The PI is already taking part in three other studies. Should the Sponsor choose this PI?
- A. No, the PI is taking part in too many ongoing studies to participate in this study.
- B. No, the PI does not have the resources to perform all protocol-required procedures.
- C. Yes, the PI can perform other imaging scans instead of the PET scans.
- D. Yes, the PI has a sufficient patient population to take part in this study.
Answer: B
Explanation:
The PI lacks access to a PET scanner, a required element for conducting the study according to the protocol.
Without this essential equipment, the PI cannot fully meet the study requirements, making it unsuitable for the sponsor to select this site. Compliance with the protocol's technical requirements is crucial for the trial's success.
GCP guidelines state that investigators must have access to all necessary facilities and equipment to conduct the trial as outlined in the protocol.
"The investigator must have adequate resources, including access to required equipment, to perform the study as specified." Objectives:
Ensure site readiness for protocol requirements.
Prevent protocol deviations due to inadequate resources.
NEW QUESTION # 69
When designing a clinical trial, why is it important to define the study population?
- A. To support the study objectives
- B. To determine where to conduct the study
- C. To support subject recruitment to the study
- D. To determine the study objectives
Answer: A
Explanation:
Defining the study population is crucial because it ensures that the trial targets the appropriate group for evaluating the investigational product (IP). A well-defined population supports the study objectives by providing reliable and interpretable data that can address the research questions.
GCP guidelines emphasize the need for a clearly defined study population to ensure the generalizability and accuracy of trial results.
"The study population must be clearly defined to ensure that the trial data are relevant and applicable to the intended patient group." Objectives:
* Enhance the scientific validity of clinical trial outcomes.
* Support the accurate interpretation of efficacy and safety data.
NEW QUESTION # 70
While reviewing reports of data completion, the sponsor notices low retention rates at many participating sites. What is an appropriate FIRST action for the sponsor to take?
- A. Interview participants who have dropped out.
- B. Submit revised ICFs to the IRB/IEC with increased compensation for participants.
- C. Require participants to provide documented reason for withdrawal.
- D. Meet with the site staff to understand their workflows and to review retention strategies.
Answer: D
Explanation:
Meeting with site staff to understand workflows and retention strategies is the most practical first step. By engaging with the team, the sponsor can identify potential issues affecting retention, such as site-related factors, participant burden, or protocol complexities. Addressing these issues collaboratively can improve retention without needing major protocol changes.
GCP guidelines recommend assessing and understanding site-specific challenges before making procedural changes or protocol amendments.
"Engaging with site staff to discuss retention issues helps identify root causes and develop practical solutions." Objectives:
* Improve participant retention through collaboration.
* Identify and address site-specific challenges.
NEW QUESTION # 71
In order to conduct open-label, parallel group clinical trials according to sound scientific principles, which of the following design elements should be included?
- A. Randomization
- B. Blinding
- C. Placebo-controlled
- D. Privacy controls
Answer: A
Explanation:
Randomization is a key element in open-label, parallel group clinical trials to reduce selection bias and ensure that participant allocation is not influenced by investigators. Despite the absence of blinding in open-label studies, randomization maintains the validity and reliability of the results by evenly distributing confounding factors between groups.
GCP guidelines recommend randomization as a core element in clinical trial design to ensure unbiased allocation of participants.
"Randomization in parallel group trials helps minimize selection bias and ensures the comparability of intervention groups." Objectives:
* Maintain scientific rigor through randomization.
* Minimize selection bias in clinical studies.
NEW QUESTION # 72
A sponsor wants a new clinical trial to be reviewed at regular intervals for progress, safety, and endpoint evaluation, and make recommendations to continue, modify, or stop the trial. How should they proceed?
- A. Conduct routine investigators' meetings
- B. Develop a monitoring plan
- C. Establish a DSMB/IDMC
- D. Draft a CAPA plan
Answer: C
Explanation:
A Data Safety Monitoring Board (DSMB) or Independent Data Monitoring Committee (IDMC) is established to review ongoing trial data at regular intervals. The DSMB evaluates safety, progress, and efficacy endpoints and makes recommendations to continue, modify, or terminate the study based on interim data. This independent oversight helps ensure participant safety and data integrity throughout the trial.
GCP guidelines recommend forming a DSMB for studies that involve high risks or long durations, ensuring continuous safety monitoring.
"The DSMB is responsible for the periodic review of accumulating data and providing recommendations regarding trial continuation, modification, or termination." Objectives:
* Ensure ongoing safety evaluation.
* Facilitate objective decisions on trial continuation.
NEW QUESTION # 73
The site submitted all start-up documents for a study to the sponsor and the IRB/IEC. The site also has subjects identified for screening. What should happen FIRST?
- A. Schedule a site initiation visit
- B. Obtain IRB/IEC approval
- C. Ship/receive IP
- D. Verify subject eligibility
Answer: B
Explanation:
Before proceeding with any trial-related activities, including subject screening, the site must first obtain IRB
/IEC approval. This approval ensures that the study has been reviewed for ethical considerations, risk assessment, and adherence to regulatory requirements. Without IRB/IEC approval, initiating the study would violate ethical guidelines and regulatory standards.
GCP guidelines mandate that no clinical trial procedures, including screening, commence without prior IRB
/IEC approval.
"IRB/IEC approval must be obtained before initiating any study-related activities, including screening and subject recruitment." Objectives:
* Ensure ethical compliance before study initiation.
* Protect participant rights and safety.
NEW QUESTION # 74
A representative from a regulatory authority shows up unannounced at a research site. After confirming their credentials, the representative requested to view the entire records, including identifiable information, from study XYZ that was closed out. Which of the following should the site personnel do next?
- A. Allow access to the entire records.
- B. Consult with the IRB/IEC first.
- C. Deny the request until the sponsor approves.
- D. Redact subject identification for privacy protection.
Answer: A
Explanation:
Regulatory authorities have the legal right to inspect clinical trial records, including identifiable information, even if the study has been closed out. After verifying the inspector's credentials, the site personnel must grant access to all requested documents to ensure compliance with regulations.
According to GCP guidelines, regulatory authorities have the right to access trial-related documents and data during inspections.
"Investigators must grant access to study records when requested by regulatory authorities as part of their inspection rights." Objectives:
* Ensure compliance with inspection requirements.
* Maintain transparency with regulatory authorities.
NEW QUESTION # 75
......
Pass ACRP ACRP-CP Exam Info and Free Practice Test: https://vcetorrent.passreview.com/ACRP-CP-exam-questions.html